Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
South Africa
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz(2,3-6,7)oxepino(4,5-c)pyrrole
2. Asenapine
3. Asenapine Maleate
4. Org 5222
5. Org-5222
6. Secuado
7. Trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole
1. Asenapine Maleate
2. 85650-56-2
3. Asenapine (maleate)
4. Sycrest
5. Asenapine Maleate [usan]
6. Org 5222
7. Org-5222
8. Cu9463u2e2
9. (z)-but-2-enedioic Acid;(2s,6s)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
10. 1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, Trans-, (z)-2-butenedioate (1:1)
11. Trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole Maleate
12. Asenapine (as Maleate)
13. (3ars,12brs)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenzo(2,3:6,7)oxepino(4,5-c)pyrrole (2z)-2-butenedioate (1:1)
14. 1h-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, (3ar,12br)-rel-, (2z)-2-butenedioate (1:1)
15. Trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole Maleate
16. Unii-cu9463u2e2
17. Einecs 288-064-8
18. Saphris (tn)
19. Org 5222 Maleate
20. Asenapine Maleate Solution
21. (s,s)-asenapine Maleate
22. Schembl175228
23. Asenapine Maleate [mi]
24. Asenapine Maleate (jan/usan)
25. Asenapine Maleate [jan]
26. Chebi:71248
27. Asenapine Maleate [mart.]
28. Dtxsid301017360
29. Hms3884e09
30. Asenapine Maleate [who-dd]
31. Asenapine Maleate [ema Epar]
32. Asenapine Maleate, >=98% (hplc)
33. Mfcd00900588
34. S1283
35. Akos015951084
36. Asenapine Maleate [orange Book]
37. Ccg-268667
38. Cs-0859
39. Mk-8274
40. Sch-900274
41. Ac-24116
42. Hy-11100
43. Sw219879-1
44. D02995
45. 650a562
46. Q27139467
47. 65576-45-6, 135883-08-8 (maleic Acid)
48. Asenapine Maleate 1.0 Mg/ml In Methanol (as Free Base)
49. (3as,12bs)-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole Maleate
50. 1h-dibenz(2,3:6,7)oxepino(4,5-c)pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-,(3ar,12br)-rel-, (2z)-2-butenedioate (1:1)
51. Trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1h-dibenzo[2,3;6,7]-oxepino[4,5-c]pyrrole Maleate
52. Trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrolemaleate
Molecular Weight | 401.8 g/mol |
---|---|
Molecular Formula | C21H20ClNO5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Exact Mass | 401.1030004 g/mol |
Monoisotopic Mass | 401.1030004 g/mol |
Topological Polar Surface Area | 87.1 Ų |
Heavy Atom Count | 28 |
Formal Charge | 0 |
Complexity | 482 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Saphris |
PubMed Health | Asenapine (By mouth) |
Drug Classes | Antipsychotic |
Drug Label | SAPHRIS is a psychotropic agent that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. The chemical designation is (3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c... |
Active Ingredient | Asenapine maleate |
Dosage Form | Tablet |
Route | Sublingual |
Strength | eq 5mg base; eq 10mg base |
Market Status | Prescription |
Company | Forest Labs |
2 of 2 | |
---|---|
Drug Name | Saphris |
PubMed Health | Asenapine (By mouth) |
Drug Classes | Antipsychotic |
Drug Label | SAPHRIS is a psychotropic agent that is available for sublingual administration. Asenapine belongs to the class dibenzo-oxepino pyrroles. The chemical designation is (3aRS,12bRS)-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1Hdibenzo[2,3:6,7]oxepino[4,5-c... |
Active Ingredient | Asenapine maleate |
Dosage Form | Tablet |
Route | Sublingual |
Strength | eq 5mg base; eq 10mg base |
Market Status | Prescription |
Company | Forest Labs |
Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Treatment of bipolar I disorder
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
N05AH05
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Sweden
Brand Name : Sycrest
Dosage Form : SUBLINGUAL TABLET
Dosage Strength : 10 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Sycrest
Dosage Form : SUBLINGUAL TABLET
Dosage Strength : 5 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Sycrest
Dosage Form : Asenapina 10Mg 60 Units Sublingual Use
Dosage Strength : 60 sublingual cpr 10 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Sycrest
Dosage Form : Asenapina 5Mg 60 Units Sublingual Use
Dosage Strength : 60 sublingual CPR 5 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Sycrest
Dosage Form : Subling Tabl
Dosage Strength : 10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Sycrest
Dosage Form : Subling Tabl
Dosage Strength : 5mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Norway
Brand Name : Sycrest
Dosage Form : Sublingvaltablett
Dosage Strength : 10 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Sycrest
Dosage Form : Sublingvaltablett
Dosage Strength : 5 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
71
PharmaCompass offers a list of Asenapine Maleate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Asenapine Maleate manufacturer or Asenapine Maleate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Asenapine Maleate manufacturer or Asenapine Maleate supplier.
PharmaCompass also assists you with knowing the Asenapine Maleate API Price utilized in the formulation of products. Asenapine Maleate API Price is not always fixed or binding as the Asenapine Maleate Price is obtained through a variety of data sources. The Asenapine Maleate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A saphris manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of saphris, including repackagers and relabelers. The FDA regulates saphris manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. saphris API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of saphris manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A saphris supplier is an individual or a company that provides saphris active pharmaceutical ingredient (API) or saphris finished formulations upon request. The saphris suppliers may include saphris API manufacturers, exporters, distributors and traders.
click here to find a list of saphris suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A saphris DMF (Drug Master File) is a document detailing the whole manufacturing process of saphris active pharmaceutical ingredient (API) in detail. Different forms of saphris DMFs exist exist since differing nations have different regulations, such as saphris USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A saphris DMF submitted to regulatory agencies in the US is known as a USDMF. saphris USDMF includes data on saphris's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The saphris USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of saphris suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The saphris Drug Master File in Japan (saphris JDMF) empowers saphris API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the saphris JDMF during the approval evaluation for pharmaceutical products. At the time of saphris JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of saphris suppliers with JDMF on PharmaCompass.
A saphris written confirmation (saphris WC) is an official document issued by a regulatory agency to a saphris manufacturer, verifying that the manufacturing facility of a saphris active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting saphris APIs or saphris finished pharmaceutical products to another nation, regulatory agencies frequently require a saphris WC (written confirmation) as part of the regulatory process.
click here to find a list of saphris suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing saphris as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for saphris API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture saphris as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain saphris and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a saphris NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of saphris suppliers with NDC on PharmaCompass.
saphris Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of saphris GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right saphris GMP manufacturer or saphris GMP API supplier for your needs.
A saphris CoA (Certificate of Analysis) is a formal document that attests to saphris's compliance with saphris specifications and serves as a tool for batch-level quality control.
saphris CoA mostly includes findings from lab analyses of a specific batch. For each saphris CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
saphris may be tested according to a variety of international standards, such as European Pharmacopoeia (saphris EP), saphris JP (Japanese Pharmacopeia) and the US Pharmacopoeia (saphris USP).